Lactobacillus johnsonii N6.2 improves glycemia and reduces diabetes-induced organ injury in the db/db mice model
Journal of Endocrinology · 2025
DOI: 10.1530/joe-25-0184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, 2025. Verfasst von Monica F Torrez Lamberti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Cell Science, Genetics Institute, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, USA. Hauptthemen laut MEDLINE: Probiotics, Diabetes Mellitus, Type 2, Lactobacillus johnsonii, Blood Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes mellitus is a complex metabolic disorder characterized by hyperglycemia and the associated comorbidities. Type 2 diabetes is also associated with the dysfunction of liver, kidney and nervous system. In addition, an altered microbiota is frequently observed in subjects with type 2 diabetes. In this study, a db/db (diabetic) mouse model of type 2 diabetes was used to elucidate the beneficial effects of the probiotic Lactobacillus johnsonii N6.2. To evaluate metabolic effects, we performed metabolomics on liver samples, and RNA-seq from the liver and visceral adipose tissue, followed by qRT-PCR validation. Using L. johnsonii N6.2 extracellular vesicles, we evaluated lipid accumulation in hepatocytes. Finally, the gut microbiome of db/db mice was profiled using 16S rRNA sequencing. We observed that administration of the probiotic improved glycemic levels and decreased diabetes scores and type 2 diabetes-associated injury to the pancreas, liver and kidneys. Liver metabolomic and transcriptome analyses identified biomarkers of L. johnsonii N6.2 activity, including modulation of the vitamin K pathway, upregulation of FGF21, a key regulator of glucose and lipid metabolism, and alternations in selected circadian genes. This study elucidates the beneficial effects of L. johnsonii N6.2, against the common symptoms of type 2 diabetes, highlighting its potential as an adjuvant therapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Cell Science, Genetics Institute, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, USA.
- Food and Nutrition Biotechnology Division, National Agri-Food and Biomanufacturing Institute (BRIC-NABI), S. A. S. Nagar, Mohali, Punjab, India.
- Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA.
- Department of Oral Biology, University of Florida, Gainesville, USA.
ORCID-Profile: Monica F Torrez Lamberti, Graciela L Lorca
Zitieren
APA
Torrez Lamberti, M. F., Thompson, S., Harrison, N. A., Gardner, C. L., da Silva, D. R., Teixeira, L. D., Kondepudi, K. K., Gonzalez, C. F., Chukkapalli, S. S., & Lorca, G. L. (2025). Lactobacillus johnsonii N6.2 improves glycemia and reduces diabetes-induced organ injury in the db/db mice model. Journal of Endocrinology. https://doi.org/10.1530/joe-25-0184
Vancouver
Torrez Lamberti MF, Thompson S, Harrison NA, Gardner CL, da Silva DR, Teixeira LD, et al. Lactobacillus johnsonii N6.2 improves glycemia and reduces diabetes-induced organ injury in the db/db mice model. Journal of Endocrinology. 2025. doi:10.1530/joe-25-0184
BibTeX
@article{TorrezLamberti2025,
author = {Torrez Lamberti, Monica F and Thompson, Sharon and Harrison, Natalie A and Gardner, Christopher L and da Silva, Danilo R and Teixeira, Leandro D and Kondepudi, Kanthi Kiran and Gonzalez, Claudio F and Chukkapalli, Sasanka S and Lorca, Graciela L},
title = {Lactobacillus johnsonii N6.2 improves glycemia and reduces diabetes-induced organ injury in the db/db mice model},
journal = {Journal of Endocrinology},
year = {2025},
doi = {10.1530/joe-25-0184}
}
EUVIMED